Amylyx Pharmaceuticals Inc

AMLX has entered a Stage 3 distribution phase after a parabolic rally and now consolidates below its declining 9- and 20-day EMAs. Price has slipped below short-term moving averages with light volume, indicating rejection at resistance and lack of strong distribution support. Medium-term bias is bearish under the distribution regime, while the long-term uptrend remains intact above the 50- and 200-day SMAs but is currently overshadowed by near-term weakness.

• ↑Phase III Lucidity trial showed significant reduction in hypoglycemic events, driving a 47% share rally.
• ↑Avexitide targets ~160k U.S. post-bariatric hypoglycemia patients; endocrinologist surveys show strong treatment intent.
• ↓FDA approval uncertainty looms over Avexitide’s planned 2027 launch.